Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 25, 1998

View Archived Issues

LeukoSite: Q3 1998 highlights

Endorex: Q3 1998 highlights

Synsorb Biotech: Q3 1998 highlights

Celgene: Q3 1998 highlights

MGI Pharma initiates phase II study of MGI-114 in pancreatic cancer patients

CytoTherapeutics receives patent protection for ocular delivery of therapeutic substances

GeneMedicine expands collaboration with Merck for GeneSwitch technology

AVI BioPharma presents advantages of CytoPorter drug delivery engine

Pentose receives SBIR grant to support Inactine development

PEG-Intron A advances to phase III trials for chronic myelogenous leukemia

Positive clinical data supports Siga's unique vaccine delivery system

Tanabe presents water-soluble taxane with better activity than paclitaxel and docetaxel

Nycomed Amersham submits MAA for Diatide's NeoTect to EMEA

New combretastatin A-4 derivative and prodrug profiled at ongoing scientific meeting

Efficacy trial of new prostate cancer treatment initiated at eight leading research centers

Ergo Science receives unapprovable letter from FDA for Ergoset

Unimed returns nitazoxanide rights to Romark

Caution recommended with zidovudine/lamivudine combination: observations of anemia reported

Dopamine D3 receptor antagonists may provide clues about receptor function

Merck & Co. synthesizes potent and orally active p38 inhibitor

Central alpha2-adrenoceptor antagonists claimed by Janssen for depression, Parkinson's disease

Herpesvirus protease inhibitors developed at SmithKline Beecham

AxyS describes new serine protease inhibitors for inflammatory disorders

Lilly's new glutamate receptor antagonists for pain

HIV integrase inhibitors under study at CNRS

FDA and Pfizer revise labeling for Viagra, issue updated information

Antipsychotic drug dropped from Novartis pipeline

First approval for Micardis

Searle revises OPUS-TIMI 16 trial evaluating orbofiban acetate

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...